Patent Move Was `Nuts,’ Regeneron CEO Tells Allergan Chief

Dec. 1, 2017, 12:11 AM

Regeneron Pharmaceuticals Inc. Chief Executive Officer Leonard Schleifer took direct aim at a fellow CEO Nov. 30, saying that Allergan Plc’s recent attempt to defend a drug patent by transferring it to native American tribe was a desperate move.

“It’s nuts,” Schleifer said at a health conference hosted by Forbes in New York. Turning to Allergan CEO Brent Saunders, who was sitting to his right, Schleifer added: “It makes your company look bad. It makes it look desperate to circumvent our system by licensing.”

Saunders disagreed, blaming a problematic legal and patent system for his company’s decision.

“The reality is, ...

To read the full article log in. To learn more about a subscription click here.